引用次数
引用: 161
H-指数: 7
I10-指数 : 6
出版物: 28
1685P Oncogenic activity of recurrent ERBB4 mutations and their sensitivity to neratinib
VK Ojala , A Tuohisto-Kokko , S Ahonen , A Jokilammi
Annals of Oncology 33 S1312
2022
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line
MKA Koivu , D Chakroborty , MZ Tamirat , MS Johnson
Databases
2020
In silico screen for predictive ERBB mutations
M Hakanen , D Chakroborty , K Kurppa , K Elenius
EUROPEAN JOURNAL OF CANCER 103 E67 -E67
2018
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases.
Marika K. A. Koivu , Deepankar Chakroborty , Mahlet Z. Tamirat , Mark S. Johnson
Molecular Cancer Therapeutics 20 ( 3) 564 -576
2021
An unbiased in vitro screen for activating epidermal growth factor receptor mutations.
Deepankar Chakroborty , Kari J. Kurppa , Ilkka Paatero , Veera K. Ojala
Journal of Biological Chemistry 294 ( 24) 9377 -9389
13
2019
L1TD1 - a prognostic marker for colon cancer.
Deepankar Chakroborty , Maheswara Reddy Emani , Riku Klén , Camilla Böckelman
BMC Cancer 19 ( 1) 1 -9
3
2019
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Elli Narvi , Katri Vaparanta , Anna Karrila , Deepankar Chakroborty
Scientific Reports 8 ( 1) 16579
5
2018
Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells
Ubaid Ullah , Syed Bilal Ahmad Andrabi , Subhash Kumar Tripathi , Obaiah Dirasantha
Cell Reports 22 ( 8) 2094 -2106
29
2018
Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target.
Juho Heliste , Anne Jokilammi , Ilkka Paatero , Deepankar Chakroborty
BMC Cardiovascular Disorders 18 ( 1) 196
3
2018
The L1TD1 Protein Interactome Reveals the Importance of Post-transcriptional Regulation in Human Pluripotency
Maheswara Reddy Emani , Elisa Närvä , Aki Stubb , Deepankar Chakroborty
Stem cell reports 4 ( 3) 519 -528
13
2015
Characterizing the oncogenic activity of ERBB4 mutations and their sensitivity to neratinib
Peppi Suominen , Deepankar Chakroborty , Kari J Kurppa , Irmina Diala
Cancer Research 81 ( 13\_Supplement) 2420 -2420
2021
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations
Deepankar Chakroborty , Veera K Ojala , Anna M Knittle , Jasmin Drexler
Cancer Research Communications 2 ( 1) 10 -27
2
2022
Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis
Majid Momeny , Mari Tienhaara , Deepankar Chakroborty , Mukund Sharma
bioRxiv 2023.06. 14.544493 -2023.06. 14.544493
2023
Database of recurrent mutations (DORM), a web tool to browse recurrent mutations in cancers
Deepankar Chakroborty , Ilkka Paatero , Kari J Kurppa , Klaus Elenius
bioRxiv 2022.11. 21.517363 -2022.11. 21.517363
2022
iSCREAM-an unbiased pipeline to screen for activating kinase mutations
Deepankar Chakroborty , Kari J Kurppa , Ilkka Paatero , Laura L Elo
Cancer Research 79 ( 13_Supplement) 1780 -1780
2019
A pipeline to identify driver mutations
Deepankar Chakroborty , Kari Kurppa , Ilkka Paatero , Laura Elo
Cancer Research 78 ( 13_Supplement) 3500 -3500
2018
Receptor Tyrosine Kinase Screening in Ischemic Heart Identifies ROR1 as a Potential Target for the Treatment of Ischemia
Juho Heliste , Ilkka Paatero , Anne Jokilammi , Deepankar Chakroborty
Circulation 136 ( suppl_1) A19681 -A19681
2017
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
Majid Momeny , Mari Tienhaara , Mukund Sharma , Deepankar Chakroborty
EMBO Molecular Medicine 1 -27
2024
Trans-activating mutations of the pseudokinase ERBB3
Marika KA Koivu , Deepankar Chakroborty , Tomi T Airenne , Mark S Johnson
Oncogene 1 -13
2024
Trans-activating mutations of the pseudokinase ERBB3
Klaus Elenius , Marika Koivu , Deepankar Chakroborty , Tomi Airenne
2023